Clinical trials: Stage III Esophageal Squamous Cell Carcinoma
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
RATIONALE: Radiation therapy uses high-energy x-rays and to kill tumor cells. Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT01107639
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- 57 sites in Austria, France and 3 more
- Volunteers
- 297 people
- Sponsor
- Swiss Cancer Institute
Esophageal Neoplasms, Squamous Cell Cancer
RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus
The purpose of the study was to test a null hypothesis that a combined modality treatment of esophageal cancer with neoadjuvant chemotherapy or chemoradiotherapy is equivalent to surgery alone and what are the benefits from…
- Trial name
- NCT00559351
- Testing
- transthoracic esophagectomy 2-field extended lymphadenectomy, neoadjuvant chemotherapy (cisplatin, 5-fluorouracil), neoadjuvant chemoradiotherapy
- Where
- Poland
- Volunteers
- 84 people
- Sponsor
- Ministry of Scientific Research and Information Technology, Poland
Esophageal Cancer
Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002884
- Testing
- chemotherapy, cisplatin, fluorouracil
- Where
- France
- Volunteers
- 326 people
- Sponsor
- Centre Hospitalier Lyon Sud
Esophageal Cancer
Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00520091
- Testing
- CPT- 11, Cisplatin, Celecoxib
- Volunteers
- 14 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC
This phase III randomized clinical trial compared the long-term survival and safety of neoadjuvant chemoradiotherapy (NCRT) followed by surgery versus surgery with adjuvant therapy (AT) in patients with locally advanced…
- Trial name
- ESCC (NCT06775652)
- Testing
- Neoadjuvant Chemoradiotherapy, Adjuvant therapy, Surgery
- Where
- China
- Volunteers
- 254 people
- Sponsor
- Yongtao Han
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04187352
- Testing
- CS1001+ Fluorouracil+Cisplatin
- Where
- 72 sites in China
- Volunteers
- 540 people
- Sponsor
- CStone Pharmaceuticals
Esophageal Squamous Cell Carcinoma
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
This trial is a registrational Phase II/III, randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with tislelizumab ± 5-FU in patients with unresectable, locally…
- Trial name
- NCT07554456
- Testing
- BL-B01D1, Tislelizumab, 5-Fluorouracil
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Stage III Esophageal Squamous Cell Carcinoma
Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC
Esophageal squamous cell carcinoma (ESCC) is one of the ten leading cancers in Taiwanese male. The prognosis is poor with a five-year overall survival rate of 10 to 30 %.
- Trial name
- NCT02812641
- Testing
- BPF-CCRT (run-in), BPF-CCRT (randomized), PF-CCRT (randomized)
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Esophageal Cancer
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and cisplatin, work in different ways to stop the growth of tumor cells, either…
- Trial name
- NCT00861094
- Testing
- cisplatin, 5-FU, oxaliplatin
- Where
- 28 sites in France
- Volunteers
- 266 people
- Sponsor
- UNICANCER
Esophageal Squamous Cell Carcinoma
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
The purpose of this study is to evaluate the efficacy and safety of KC1036 versus investigator's choice of chemotherapy in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma
- Trial name
- NCT06194734
- Testing
- KC1036, Irinotecan, Docetaxel
- Where
- China
- Volunteers
- 490 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Stage I Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma
Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer
The therapy of photofrin PDT was effective in improving life quality of patients with advanced esophageal and/or gastric cardiac cancer and the time optimizing for employing laser irradiation was of great importance.The purpose…
- Conditions
- Stage I Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage I Esophageal Squamous Cell Carcinoma
- Trial name
- NCT02628665
- Testing
- photosensitizer(photofrin), 630 nm laser irradiation (DIOMED)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
This is a randomized, controlled, multi-center phase II/III study. All patients are resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT07263919
- Testing
- Cadonilimab (AK104), Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Esophageal Cancer, Gastric Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00005638
- Testing
- cisplatin, irinotecan hydrochloride, radiation therapy
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Cancer
Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tumor…
- Trial name
- NCT00290719
- Testing
- cisplatin, gefitinib, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Esophageal Cancer, Gastric Cancer
Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005599
- Testing
- bryostatin 1, paclitaxel
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
This study examines at-home monitoring of patient-generated phsyiologic health data and patient-reported outcomes. Patient-generated health data using at-home monitoring devices and smart device applications are used more and…
- Conditions
- Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04501913
- Testing
- Patient Monitoring, Questionnaire Administration
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- City of Hope Medical Center
Esophageal Squamous Cell Carcinoma
A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
This study is a randomized, double-blind, multi-center, phase III clinical study comparing the clinical efficacy and safety of HLX10 or placebo combined with chemotherapy in first-line treatment of locally advanced/metastatic…
- Trial name
- NCT03958890
- Testing
- HLX10 100 mg in 10 ml Injection
- Where
- 7 sites in China
- Volunteers
- 489 people
- Sponsor
- Shanghai Henlius Biotech
Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study
This study evaluates how the treatment for gastroesophageal cancer affects physical function in patients who receive chemotherapy as part of their treatment for gastroesophageal cancer.
- Conditions
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT07517211
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Esophageal Cancer
Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma
Definitive chemoradiation is the standard treatment for locally advanced esophageal cancer. NCCN (National Comprehensive Cancer Network) recommends radiation dose of 50-50.4 Gy as the definitive radiation dose for esophageal…
- Trial name
- NCT02850991
- Testing
- High-dose, Standard-dose
- Where
- China
- Volunteers
- 167 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Cancer
Irinotecan, Radiation Therapy, and Docetaxel With or Without Cisplatin in Treating Patients With Locally Advanced Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00601692
- Testing
- cisplatin, docetaxel, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Memorial Sloan Kettering Cancer Center